Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Engage Grants Program

University of Toronto

$22,000.00

Validation of Drosophila as a model to identify anti-lipogenic and anti-diabetic compounds.

FY 2013-14

Summary
In the past decade, obesity has been recognized as an increasing threat to the global health of children and adults, with numerous associated life-threatening complications, including diabetes, heart disease, hypertension and cancer. Obesity is a complex disorder that is the result of the interaction between predisposing genetic and environmental factors. However, the precise nature of these gene-gene and gene-environment interactions, remain unclear. The Boulianne lab has taken advantage of powerful genetic approaches available in the fruit fly, Drosophila melanogaster, to identify mutations in genes that give rise to obese flies and to determine how various diets (e.g. high fat and high sugar) affect the phenotypes of obese flies. BioAspect Inc. is a Canadian company whose goal is to provide customers with robust in vitro and in vivo assays that can be used for drug discovery. The goal of the proposed research is to determine whether Drosophila models can be used as an in vivo platform to identify drugs that can be used to treat obesity and diabetes. Specifically, we will use two existing fly models of obesity that have been developed in the Boulianne lab and establish a new model of diabetes by maintaining flies on a high sugar diet. We will then determine whether known anti-diabetic and anti-obesity drugs are effective in Drosophila thereby validating the model for future drug discovery.
Program
Engage Grants Program
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
461968-2013
Name nom
Boulianne, Gabrielle
Department département
Molecular Genetics
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2013
Competition year année de concours
2013
Award amount
22000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
5003
Research subject group en
Genetics
Research subject group fr
Génétique
Research subject en
Developmental genetics
Research subject fr
Génétique du développement
Partie
1
Nb partie
1
Application title
Validation of Drosophila as a model to identify anti-lipogenic and anti-diabetic compounds.
Keyword
NSERC
Application summary
In the past decade, obesity has been recognized as an increasing threat to the global health of children and adults, with numerous associated life-threatening complications, including diabetes, heart disease, hypertension and cancer. Obesity is a complex disorder that is the result of the interaction between predisposing genetic and environmental factors. However, the precise nature of these gene-gene and gene-environment interactions, remain unclear. The Boulianne lab has taken advantage of powerful genetic approaches available in the fruit fly, Drosophila melanogaster, to identify mutations in genes that give rise to obese flies and to determine how various diets (e.g. high fat and high sugar) affect the phenotypes of obese flies. BioAspect Inc. is a Canadian company whose goal is to provide customers with robust in vitro and in vivo assays that can be used for drug discovery. The goal of the proposed research is to determine whether Drosophila models can be used as an in vivo platform to identify drugs that can be used to treat obesity and diabetes. Specifically, we will use two existing fly models of obesity that have been developed in the Boulianne lab and establish a new model of diabetes by maintaining flies on a high sugar diet. We will then determine whether known anti-diabetic and anti-obesity drugs are effective in Drosophila thereby validating the model for future drug discovery.